Promontory Therapeutics is a private, clinical-stage drug development company focusing on oncology therapeutics, running multiple clinical trials in the US and Europe.
The company’s clinical lead, PT-112, has a pleiotropic mechanism of action and induces immunogenic cell death (ICD), leading to an adaptive immune response.
Sponsored Ad
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.